The Danish meningococcal disease laboratory surveillance system was established in 1974, based on close collaboration between local Departments of Clinical Microbiology and the Reference Laboratory at Statens Serum Institut. The completeness of the clinical notification system integrated with the laboratory surveillance system has been estimated to be more than 95%. Overall 4257 (79 %) of 5356 cases of meningococcal disease notified during 1974-1999 were confirmed by culture of Neisseria meningitidis. The proportion of culture-confirmed cases ranged from 70 % in 1989 to 89 % in 1980. Only 26 patients (0 . 6 %) with culture-confirmed meningococcal disease were not notified. Serological phenotype and susceptibility to penicillin and sulphonamide were determined for all isolates. Multilocus enzyme electrophoresis and/or DNA-based analyses were used for the assessment of clusters and outbreaks. Meningococcal antibody tests and counter-immunoelectrophoresis were used for the ascertainment of suspected cases. These combined systems allowed timely and reliable management of outbreaks and identification of clusters.
INTRODUCTION
In Denmark, surveillance and prevention of communicable diseases have been regulated by royal prescripts and governmental circulars for more than 200 years. The notification system for meningococcal disease (epidemic meningitis) was established in 1867. Figure 1 illustrates changes in incidences of meningococcal disease during the nineteenth century. As in some other European countries [1, 2] and the U.S. Army [3] epidemics occurred during World War I and World War II. Notifications were not available from 1963 to 1967.
In 1974 the compulsory clinical notification system was supplemented with a voluntary laboratory surveillance system based on close collaboration between local Departments of Clinical Microbiology and the National Neisseria Reference Laboratory at the Statens Serum Institut. At that time vaccines protecting against serogroup C meningococcal disease had become available [4] and in 1974 the newly developed serogroup A vaccine [5] was found to be effective during an epidemic caused by sulphonamideresistant serogroup A meningococci in Finland [6] . It was, therefore, considered important to monitor the proportions of invasive meningococcal strains by serogroup, and to evaluate laboratory methods that could be useful in the ascertainment of clinically suspected, but culture-negative cases of meningococcal disease. Further methods for determination of epidemiological markers were subsequently established and found to be useful tools in the detection and investigation of clusters of cases or outbreaks of meningococcal disease.
In this paper we describe the development of services at the Danish Reference Laboratory and how laboratory surveillance data was integrated with information from the compulsory clinical notification system, which had been administered by the Department of Epidemiology, Statens Serum Institut from 1980. Recent analysis showed that this active and integrated surveillance system was highly efficient, probably identifying more that 95% of all cases of meningococcal disease occurring in the country [7] .
METHODS

Laboratory surveillance system
From 1974, a panel of laboratory methods for determination of epidemiological markers was gradually established. When a patient with clinically suspected meningococcal disease is admitted to hospital the attending physician must inform the local Medical Officer of Health (MOH) by telephone and also the Department of Epidemiology at the Statens Serum Institut by mailing a completed Communicable Disease Notification Form. The local Department of Clinical Microbiology refers any meningococcal isolate from the patient to the reference laboratory at Statens Serum Institut as soon as available. Serogrouping is performed without delay and the MOH as well as the Department of Epidemiology are informed about the receipt of the meningococcal isolate and the result of serogrouping. If the isolate belongs to a serogroup uncommon among invasive strains (W-135, 29E, X, Y, Z) the attending physician is notified that the prevalence of complement deficiency is increased in this selected group of patients. Isolates are stored in liquid nitrogen until further characterization can be carried out, and then lyophilized. The strain collection at the reference laboratory comprises all strains received since 1974 ; in addition, selected materials from the period 1940-1973 have been kept as lyophilized samples.
The laboratory analyses available fall into three categories : tests performed routinely, tests performed on request and supplementary tests used when discrimination between phenotypically identical strains is needed.
Tests performed routinely
Serological phenotyping
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Antimicrobial susceptibility testing
All strains were tested for susceptibility to penicillin and to sulphonamide (sulphamethoxazole). In addition, all strains were examined for susceptibility to other antibiotics in current use for the prevention of secondary cases of meningococcal disease (rifampicin from 1982 to 1992, ciprofloxacin since 1993). Strain susceptibility to sulphamethoxazole, penicillin, and ciprofloxacin was determined by the agar incorporation method. Resistance to rifampicin was detected by an agar disc diffusion method. Rifampicin. The disc content was 30 mg rifampicin at which load the inhibition zones for resistant strains are zero.
Tests performed on request
Counter-immunoelectrophoresis (CIE ) Direct detection of meningococcal capsular polysaccharides A, B and C was performed as previously described [10] .
Meningococcal antibody test (MAT )
The MAT is an in-house complement fixation test using heat-killed whole cells from a pool of meningococcal strains as antigen and fresh guinea-pig serum as complement source. The result is expressed as degree of potency (DP). Either seroconversion to o3 DP or a change in titre of o3 DP were considered indicative of current meningococcal infection [11] .
ELISAs
The assays used for detection of serogroup B-specific (IgM) and serogroup C-specific (IgM and IgG) antibodies have been described previously [12] .
Supplementary tests
Multilocus enzyme electrophoresis (MEE) and DNA fingerprinting (DFP) were performed as previously described in detail [13] , pulsed-field gel electrophoresis (PFGE) was performed as described by Bygraves and Maiden [14] and ribotyping was performed using an automated system (Ribo Printo, Qualicon, USA) as described by Jensen et al. [15] .
RESULTS
Overall 4257 (79 %) of 5356 cases of meningococcal disease notified from 1974 to 1999 were confirmed by culture of N. meningitidis. Except in 1974, the year in which the laboratory surveillance system was initiated, the proportion of known culture-confirmed cases ranged from 70 % in 1989 to 89 % in 1980. The curves in Figure 2 illustrate that the annual number of notified cases of meningococcal disease and the annual number of culture-confirmed cases concordantly reflect changes in the prevalence of disease. During the whole period the referral rate was close to 100 % and very few strains were lost before or during transport to the reference laboratory (Lind, I. & Berthelsen, L., unpublished data). In total we received 5157 isolates from 4283 patients. Thus, 26 patients with cultureconfirmed meningococcal disease (0 . 6 %) had not been notified. Roughly the diagnosis was confirmed by culture of meningococci from cerebrospinal fluid (CSF) in half of the patients, from blood in one third and from both these sites in the remaining sixth part. In a few cases isolates from petechiae (n=18), joint fluid (n=2), eye secretions (n=3), etc. were received, most often together with an isolate from blood or spinal fluid. N. meningitidis strains isolated from nasopharyngeal swabs from patients hospitalized with meningococcal disease were also accepted for serogrouping.
Determination of epidemiological markers
In general, all isolates received were examined for all epidemiological markers applied at that time and where epidemiologically relevant.
Serological phenotyping
In 1974 serogroup A was predominant in Denmark, but it disappeared rapidly and during the past 15 years only a few sporadic cases have occurred (Fig. 3) . Serogroup A strains were replaced by serogroup B, and partly by serogroup C strains ; these two serogroups accounted for more than 95% of all cases of meningococcal disease. The remaining cases were caused by serogroups W-135, 29E, X, Y, Z and by non-groupable strains. A high proportion of these cases occurred in complement-deficient persons [16] and in recent years, also in HIV-seropositive patients. From 770 patients, two or more isolates were subjected to serogrouping. Simultaneous isolates from CSF and blood were available from 491 patients ; in only two patients (0 . 4 %) were discrepant results found and in both cases the isolates from the spinal fluid were groupable and the isolates from blood nongroupable. From 186 patients we received a pharyngeal isolate together with an isolate either from CSF or blood ; in one patient (0 . 5 %) the pharyngeal isolate belonged to another serogroup (Y) than that found in the CSF (B).
Concurrently with the introduction of serosubtyping in 1987, the typing method was changed from co-agglutination to ELISA. All strains from 1987 were serotyped by both methods; the change of method resulted in a significant decrease in the proportion of non-typable (NT) strains (Tables 2 and 3) , especially for serogroup C strains, among which 64 % and 12% were NT by co-agglutination and ELISA respectively. Most of this decrease was attributable to a better performance of the type 2a monoclonal antibody by the latter method. The percentage of NT strains among serogroup B strains as well as among serogroup C strains decreased from 1992 to 1993 without any associated change in method or in the panel of typing reagents employed. However, a new kit of type-specific monoclonal antibodies was used from January 1993. The introduction of type 21 and type 22 reagents in 1996 brought no changes. The number of serosubtyping reagents was raised in 1993. Subsequently, the percentage of non-subtypable (NST) strains within both serogroups decreased. NT/ NST strains became as rare among serogroup C strains as they had already been among serogroup B strains since 1987 (Tables 2 and 3) .
In 1985 a retrospective collaborative study on meningococcal serotype and serogroup B disease in North-West Europe [17] included approximately 20 Danish serogroup B strains from each year from 1974 to 1983. This study showed that the phenotype B :15 was introduced in Denmark in 1976 followed by a rise in prevalence of meningococcal disease (Fig. 2) . Within few years B :15 (B :15 :P1.7,16) strains accounted for 50-60 % of all serogroup B strains including the periods before and after 1985-1986, where a 60 % increase in the incidence of meningococcal disease occurred (Fig. 2) [1974] [1975] . The reference strains have been included in each experiment ever since and they have proved to be stable. Table 4 illustrates that sulphonamide-resistant meningococcal strains occurred in Denmark in the early 1940s, disappeared in the 1960s and then emerged again in 1972 [20] . The old strains were tested in 1982; they originated from patients with meningococcal disease and were available at the strain collection kept at the reference laboratory. All serogroup A strains isolated in 1974 were sulphonamide resistant, but as the serogroup A strain disappeared, (Table 5) .
Penicillin. Tables 6 and 7 Rifampicin. During the 10-year period (1983) (1984) (1985) (1986) (1987) (1988) (1989) (1990) (1991) (1992) in which rifampicin treatment was recommended for prevention of secondary cases among household and similar close contacts, a total of three (0 . 12 %) of 2359 invasive strains were found to be rifampicin resistant and only one of these strains was from a secondary case in a rifampicin-treated sibling of a girl in whom onset of disease occurred 1 week before and from whom a phenotypically identical, rifampicinsusceptible strain was encountered [21] .
Ciprofloxacin. All 1212 strains isolated from patients with meningococcal disease in the period 1993-1999 were fully susceptible to ciprofloxacin (MIC f0 . 004 mg/l). Further, 390 invasive strains isolated from November 1990 to the end of 1991, and 1992, i.e. before ciprofloxacin became first-choice drug for prophylaxis, were fully susceptible. 1993 218  2  23  125  56  11  1  1994 193  1  16  102  62  12  0  1995 178  0  11  117  45  4  1  1996 177  3  0  85  74  15  0  1997 174  2  5  103  57  6  0  1998 120  3  20  81  12  3  1  1999 152  3  10  84  44  11  0 MIC, Minimum inhibitory concentration.
MEE and DNA-based analyses ( fingerprinting, PFGE, riboprinting)
The usefulness of these methods for the study of the epidemiology of meningococcal disease in our setting has been discussed previously [13, 22, 23] . Our conclusions were that invasive strains from epidemiologically related cases (outbreaks, clusters) were reliably identified by phenotyping whereas determination of the relationship between carrier strains and invasive strains or with epidemiologically unrelated strains of identical phenotypes required application of one or more supplementary tests.
Ascertainment of suspected cases
Serology MAT (meningococcal antibody test). In a study on the usefulness of the MAT in the diagnosis of meningococcal disease [11] 90% of patients with cultureconfirmed meningococcal disease were found to be seropositive 10-15 days after onset of disease; the majority of patients were MAT-negative at onset of disease, i.e. on the day of hospitalization. Since 1992 MOHs and the Department of Epidemiology have been informed if seroconversion or a significant increase in antibody titres was demonstrated in a patient who had not been identified through the laboratory surveillance system. Since then an increasing proportion of cases notified without culture-confirmed diagnosis have been registered as serologically confirmed [11] . In 1999 22 out of 35 cases (63 %) not confirmed by culture of N. meningitidis were recorded as serologically confirmed [24] .
ELISAs (antibodies specific to meningococcal polysaccharides B and C). The performances of the ELISAs have previously been described in detail [12] . Among patients with culture-confirmed meningococcal disease, antibodies specific for the capsular polysaccharides can be demonstrated in 79-92%. ELISAs are less sensitive than the MAT for the diagnosis of meningococcal disease [25] , but allow serological discrimination between serogroup B and C disease. Since 1992 sera from culture-negative, serologically confirmed, i.e. MAT-positive, cases were examined by ELISA and the results suggested that the proportions of serogroup B and C disease were the same as among culture-confirmed cases of meningococcal disease.
Counter-immunoelectrophoresis (CIE). The test was made available for use on serum or CSF from patients in whom early antibiotic treatment had ruled out the possibility of recovering N. meningitidis by culture. In addition to a previous study on CSF samples [10] we carried out investigations on acute serum samples (Berthelsen, L., unpublished data) -134 samples from patients with culture-confirmed meningococcal disease and 75 samples from patients with serological evidence of meningococcal disease (seroconversion in MAT), but in whom the diagnosis had not been confirmed by culture. All sera were collected during the period 1986-1990. For culture-confirmed cases the overall sensitivity was 44 % ; for sera drawn on days 0, 1 or 2 after onset of disease the sensitivity was 44, 61 and 18 % respectively. For serologically confirmed cases it was 25 %; acute samples from 44 patients with meningitis caused by various other microorganisms were negative. In 1992 we decided further to assess whether CIE performed routinely on all acute serum samples received for MAT would contribute to an early diagnosis in suspected cases. The material comprised sera from 140 patients : 36 culture-confirmed cases, 15 with serological evidence of meningococcal disease and 89 without meningococcal disease. Doubtful results, i.e. those with weak indistinct precipitate with the serogroup B antiserum turned out to be a problem. Regardless of whether the doubtful results were considered positive or negative, the sensitivity of CIE was lower than that found previously, namely 22 % and 24 % respectively. The predictive values of the positive test results under the same conditions were 61 % and 44%. CIE is, therefore, only offered as a supplementary test on request. MAT-positive sera have never been found positive by CIE.
DISCUSSION
When laboratory surveillance of culture-confirmed meningococcal disease in Denmark was established in 1974, the primary objective was to ensure optimal and prompt use of the newly developed serogroup A and C capsular polysaccharide vaccines [4, 5] and to monitor the susceptibility of invasive meningococcal strains to antibiotics used for treatment and for the prevention of secondary cases. Due to the poor immunogenicity of the serogroup B capsular polysaccharide, attempts to develop a vaccine protecting against serogroup B disease have involved many bacterial components, including the proteins determining type and subtype specificity. The considerable antigenic diversity among serogroup B meningococcal strains has resulted in a variety of serotype/subtype combinations. Antibodies to any single protein are unlikely to provide broad protection against serogroup B meningococcal disease [26] . Approaches to vaccine development have been based on proteins from epidemic strains as B :15 :P1.7,16 or on serosubtype-determinating proteins from the most predominant endemic, invasive strains. To address the potential usefulness of such vaccines it was considered important to monitor the prevalence of serogroup B phenotypes as defined by their serotype/ serosubtype patterns. Monoclonal reagents for typing and subtyping became available in the mid-1980s and have since been used in the majority of European reference laboratories. To assess the performance of these reagents an international comparative study [27] was carried out. The study concluded that serological typing could be standardized, and thus, be a useful tool in vaccine development projects. It is a prerequisite that the panel of antibodies is broad and currently updated. However, the inclusion of serotypes 21 and 22 reagents in 1996 did not decrease the percentage of NT strains in spite of the fact that type 22 made up more than 60 % of serogroup B strains in a neighbouring country (Poland) at that time [28] . Since the typing system was found useful in the assessment of clusters and outbreaks it has been maintained, although potent serogroup B vaccines seem still to be unattainable in the near future.
Determination of susceptibility to sulphonamides was an integrated part of the surveillance system from its establishment in 1974. The reference strains were selected and evaluated in that year and have been used in all tests since. The MIC results were highly reproducible. The reappearance of sulphonamideresistant strains in 1972 coincided with both an increased prevalence of serogroup A strains and the introduction of cotrimoxazole on the Danish market. Sulphonamide resistance is nearly always present in epidemic strains [13, [18] [19] [20] 22] and is a useful epidemiological marker.
Penicillinase-producing Neisseria gonorrhoeae (PPNG) emerged in Denmark in March 1976. Since 1 April 1976, the susceptibility to penicillin of all invasive meningococcal strains has been determined ; strains from 1975 and the first three months of 1976 were tested retrospectively. Penicillin-resistant meningococcal strains were not detected. Worldwide production of penicillinase in N. meningitidis isolates from patients with invasive meningococcal disease has been reported in only four cases occurring in South Africa [29] and Spain [30] . There was no trend over time in the distribution of penicillin MICs among invasive N. meningitidis (Tables 6 and 7 ). The proportion of strains from 1993 to 1999 that might be designated less susceptible or moderately susceptible (MIC 0 . 125-1 mg/l) [31] was constant. This is in contrast to the changes recorded in Spain [32] and Australia [33] .
During a 10-year period from 1982 to 1992 rifampicin was recommended for the prevention of secondary cases. Within this period only three resistant strains (0 . 12 %, 3/2456) were recovered ; one of the three was found in a patient with meningoccal disease who had received prophylactic treatment with rifampicin 1 week before onset of illness [21] . Over the 10-year period about 10 000 close contacts of sporadic cases of meningococcal disease had received rifampicin prophylaxis. Thus, the standard regimen used for prevention of secondary cases did not seem to confer any significant risk of increasing the prevalence of resistance ; the same conclusion has been drawn from surveillance studies in other countries [31, 32] . Rifampicin treatment prevents secondary cases [18, 34, 35] and when a more liberal definition of the target group is used, it may also modify the curves of epidemics [18, 35] .
Since 1993 a 500-mg single dose of ciprofloxacin has been recommended for prophylactic use in Denmark. All strains tested during the preceding 2-year period as well as all strains isolated during 1993-1999 were fully susceptible. Only a single report of decreased susceptibility to ciprofloxacin in one N. meningitidis isolate (MIC 0 . 25 mg/l) has been published [36] .
The introduction of supplementary tests (MEEand DNA-based analyses) in the assessment of clusters and outbreaks was based on the studies of Weis & Lind [13, 22] . These methods also permitted a more precise identification of distinctive clone complexes [15] associated with an increased case-fatality rate among patients with phenotype B :15 :P1.7,16 and C :2a :P1.2,5 meningococcal disease [37] . Similarly, the supplementary tests facilitated identification of virulent strains among carriers of potentially invasive phenotypes [19, 22, 23] . The overall conclusion is that in the epidemic situation phenotyping is sufficient for decision making [22, 38] whereas tracing of potentially virulent strains among carriers requires DNA-based characterization.
